Recently published in the peer-reviewed journal Diabetes Therapy, clinical data highlights that a standard dose of vitamin C and 30 minutes of moderate exercise produce no clinically meaningful change in the accuracy of the iCan continuous glucose monitoring (CGM) system. Across 2,168 paired readings spanning across measurement range, 92.0% of values agreed with venous reference measurements within 20/20%, and no serious adverse events occurred. The Agreement Rates of the iCan CGM System seen in this study are similar to data reported with the same device in a later study in Germany (6).
This published paper may be found here: https://doi.org/10.1007/s13300-026-01918-9.

Two limitations have followed CGM since its introduction: certain substances can distort the sensor’s signal, and physical activity can do the same. Both arise in ordinary life, sometimes at the moment when a reliable reading shapes a treatment decision. The iCan sensor is built on flavin adenine dinucleotide-dependent glucose dehydrogenase (GDH-FAD) technology, an enzyme that, unlike the glucose oxidase used in most CGM systems, does not use oxygen as an electron acceptor. The study tested whether that difference holds under controlled conditions in a USA study site.
Sixteen adults with type 1 diabetes wore three sensors at two sites, abdominal and back of upper arm, for the full 15-day wear period and attended three in-clinic visits for frequent blood sampling against a YSI 2300 STAT PLUS reference. At two visits they completed 30 minutes of moderate exercise between pronounced glucose excursion meals and were randomized to take 1,000 mg of ascorbic acid before the first meal. With ascorbic acid, MARD changed by −1.6% and mean absolute difference by −1.1 mg/dL; after exercise, MARD changed by −1.5% and mean absolute difference by −1.3 mg/dL. Neither was considered clinically meaningful, and only 0.2% of readings fell outside the widest 40/40% boundary.
Four adverse events occurred in two participants, three at the insertion site and one gastrointestinal; all were mild, with no serious or severe events. The authors attribute the result to the GDH-FAD enzyme together with the sensor’s third-generation architecture, noting that earlier CGM sensors, including several widely used CGM systems, have been affected by ascorbic acid which may interfere with accurate functioning of some, resulting in falsely elevated glucose measurements.
For patients the value is practical. A reading not artificially raised by vitamin C gives a more dependable basis for a correction dose, reducing the risk of over-correcting and the hypoglycemia that can follow. Accuracy that holds through moderate exercise means the sensor can be relied on before, during and after activity, and patients need not time supplements around sensor wear.
The GDH-FAD technology is built into the study device, True Vie i3 CGM in the United States, similarly the device is known as GlucoMen® iCan and iCan i3 in Europe and is registered in numerous regulated markets worldwide.
The study adds to a clinical program spanning more than 500 participants across completed studies in the United States, Europe and Asia. The full article is available open access in Diabetes Therapy.
About Sinocare iCan CGM System
Sinocare iCan CGM System is one of the most widely clinically studied continuous glucose monitoring systems in the world.1, 2, 3, 4, 5, 6
More than 500 people with type 1 and type 2 diabetes have participated in our world-wide clinical studies, and most clinical study participants have been assessed at sites in either the United States of America or in the Federal Republic of Germany. ~ 60.95% of 507 worldwide iCan CGM system clinical study subjects are people living with diabetes in either the USA or in Europe.
iCan CGM clinical study citations:
Enrolment n=159 https://clinicaltrials.gov/study/NCT05806554 a completed study in adults.(1)
Enrolment n=134 https://clinicaltrials.gov/study/NCT05908448 a completed study in children.(2)
Enrolment n=78 https://doi.org/10.1177/19322968261463536 a completed study in children.(3)
Enrolment n=16 https://doi.org/10.1007/s13300-026-01918-9. a completed study in adults.(4)
Enrolment n=120 DOI: https://doi.org/10.3969/j.issn.1006-6187.2026.05.004 a completed study in adults.(5)
Enrolment n=35 https://doi.org/10.1007/s13300-025-01832-6 a completed study in adults. (6)
About Sinocare
Established in 2002, Sinocare is the first blood glucose meter company to be listed in China, and also the largest manufacturer of glucose monitoring devices in China. With a commercial presence in Asia, Europe and North America, Sinocare has expanded internationally through partnerships and acquisitions such as the USA based PTS Diagnostics Inc. and Trividia Health Inc., pioneering a digital management ecosystem for diabetes and chronic conditions by integrating “Biosensing + AI + Healthcare.” We provide global users and healthcare professionals with innovative products and smart medical solutions that seamlessly span prevention, monitoring, and long-term care. Today, our core portfolio comprises four strategic pillars: Personal Palm Labs, Precision Desktop Labs, Precision Wearable Systems, and Digital Diabetes Management Solutions.
Remaining steadfastly user-centric, Sinocare has built a global R&D and manufacturing infrastructure. By delivering accurate, easy-to-use, and affordable solutions, we break down the barriers of chronic disease management, bringing medical-grade diagnostics and digital health services into millions of households worldwide. By synergizing “AI Agents, Chronic Disease Expertise, and Continuous Behavioral Support,” Sinocare delivers an ecosystem of ongoing patient companionship, translating cutting-edge technology into tangible, life-changing health outcomes.